Gardasil
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Human Papillomavirus Infection
Conditions
Human Papillomavirus Infection
Trial Timeline
Oct 1, 2009 → Aug 1, 2011
NCT ID
NCT00925288About Gardasil
Gardasil is a approved stage product being developed by Merck for Human Papillomavirus Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00925288. Target conditions include Human Papillomavirus Infection.
What happened to similar drugs?
13 of 20 similar drugs in Human Papillomavirus Infection were approved
Approved (13) Terminated (4) Active (7)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04022148 | Pre-clinical | UNKNOWN |
| NCT01432574 | Phase 2 | Completed |
| NCT01741012 | Phase 1 | Completed |
| NCT01338051 | Phase 1 | Completed |
| NCT00925288 | Approved | Completed |
| NCT01133509 | Pre-clinical | UNKNOWN |
| NCT00786409 | Pre-clinical | Completed |
| NCT00666107 | Pre-clinical | UNKNOWN |
Competing Products
20 competing products in Human Papillomavirus Infection